Man Group
DNLI icon

Man Group’s Denali Therapeutics DNLI Stock Holding History

Man Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.58M Buy
139,065
+20
+0% +$411 0.01% 1290
2026
Q1 		$2.67M Buy
139,045
+90,051
+184% +$1.79M ﹤0.01% 1442
2025
Q4 		$809K Buy
+48,994
New +$827K ﹤0.01% 1742
2025
Q3 		– Sell
-70,028
Closed -$980K – 2273
2025
Q2 		$980K Sell
70,028
-99,357
-59% -$1.4M ﹤0.01% 1636
2025
Q1 		$2.3M Buy
169,385
+146,950
+655% +$2.82M 0.01% 1310
2024
Q4 		$457K Sell
22,435
-7,992
-26% -$205K ﹤0.01% 1699
2024
Q3 		$886K Sell
30,427
-7,118
-19% -$176K ﹤0.01% 1531
2024
Q2 		$872K Buy
+37,545
New +$721K ﹤0.01% 1543
2023
Q3 		– Sell
-505,214
Closed -$12.8M – 677
2023
Q2 		$14.9M Buy
+505,214
New +$14.2M 0.05% 479
2023
Q1 		– Sell
-142,929
Closed -$3.97M – 2114
2022
Q4 		$3.97M Buy
142,929
+108,508
+315% +$3.23M 0.01% 907
2022
Q3 		$1.06M Buy
+34,421
New +$1.12M ﹤0.01% 1269
2021
Q3 		– Sell
-5,464
Closed -$429K – 1942
2021
Q2 		$429K Sell
5,464
-53,061
-91% -$3.28M ﹤0.01% 1607
2021
Q1 		$3.34M Sell
58,525
-41,117
-41% -$2.75M 0.01% 889
2020
Q4 		$8.35M Sell
99,642
-51,814
-34% -$3.13M 0.04% 518
2020
Q3 		$5.43M Buy
+151,456
New +$4.56M 0.02% 768
2018
Q4 		– Sell
-10,488
Closed -$228K – 1960
2018
Q3 		$228K Buy
+10,488
New +$173K ﹤0.01% 2000

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Man Group's DNLI Position: Q2 2026 in Review

Man Group increased its Denali Therapeutics (DNLI) stake by 0.01% in Q2 2026, buying an estimated $411 and bringing the position to 139,065 shares worth $3.58M. The position accounts for 0.01% of the portfolio, ranked #1290.

Man Group first reported a position in DNLI in Q3 2018 and has held it in 16 quarters since. The position peaked at $14.9M in Q2 2023. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Man Group held 139,065 shares of Denali Therapeutics worth $3.58M as of Q2 2026.
  • Man Group bought 20 Denali Therapeutics shares in Q2 2026, an estimated $411.
  • Denali Therapeutics made up 0.01% of Man Group's portfolio in Q2 2026, its #1290 holding.
  • Man Group first reported a position in Denali Therapeutics in Q3 2018 and has held it in 16 quarters since.
  • Man Group's Denali Therapeutics position peaked at $14.9M in Q2 2023.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.